Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-09-26
2006-09-26
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S387300, C530S399000
Reexamination Certificate
active
07112659
ABSTRACT:
The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5169318 (1992-12-01), Levy
patent: 5225538 (1993-07-01), Capon et al.
patent: 5284656 (1994-02-01), Platz et al.
patent: 5349053 (1994-09-01), Landolfi et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5594101 (1997-01-01), Becker et al.
patent: 5594104 (1997-01-01), Basinski et al.
patent: 5646040 (1997-07-01), Kleyn et al.
patent: 5670625 (1997-09-01), Lyman et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5935810 (1999-08-01), Friedman et al.
patent: 6001968 (1999-12-01), Friedman et al.
patent: 6025325 (2000-02-01), Campfield et al.
patent: 6048837 (2000-04-01), Friedman et al.
patent: 6350730 (2002-02-01), Friedman et al.
patent: 2205572 (1995-12-01), None
patent: 2195955 (1996-02-01), None
patent: 2224646 (1997-01-01), None
patent: 2238307 (1997-07-01), None
patent: 306673 (1989-03-01), None
patent: 401384 (1989-12-01), None
patent: 362999 (1990-04-01), None
patent: 417563 (1991-03-01), None
patent: 464533 (1992-01-01), None
patent: 956862 (2002-12-01), None
patent: WO 89/10932 (1989-11-01), None
patent: WO 91/11111 (1991-08-01), None
patent: WO 92/13559 (1992-08-01), None
patent: WO 94/06476 (1994-03-01), None
patent: WO 96/03141 (1996-02-01), None
patent: WO 96/04388 (1996-02-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/18412 (1996-06-01), None
patent: WO 96/22308 (1996-07-01), None
patent: WO 96/31526 (1996-10-01), None
patent: WO 97/00319 (1997-01-01), None
patent: WO 97/18833 (1997-05-01), None
patent: WO 97/24137 (1997-07-01), None
patent: WO 97/24440 (1997-07-01), None
patent: WO 98/28427 (1998-07-01), None
patent: WO 98/46257 (1998-10-01), None
patent: WO 99/02711 (1999-01-01), None
patent: WO 99/22764 (1999-05-01), None
Abuchowski, A., et al., “Soluble Polymer-Enzyme Adducts,”Enzymes as Drugs(J.S. Holcerberg and J. Roberts, eds.) 367-383 (1981).
Adjei et al.,Int'l. J. of Pharm., 61:135-144 (1990).
Adjei, et al.,Pharm. Res., 7(6):565-569 (1990).
Ashkenazi, A., et al.,A Companion to Methods in Enzymology, 8:104-115 (1995).
Ashkenazi, A., et al., “Protection Against Edotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin,”PNAS USA, 88:10535-39 (1991).
*Attwood, T., et al., “The Babel of Bioinformatics,”Science, 290(5491):471-473 (Oct. 2000).
Bachmann, et al.,Bacteriol. Rev., 40:116-167 (1976).
Barinaga, M. “Obese' Protein Slims Mice,”Science, 269:475-476 (1995).
Bennett, B. et al., “Estracellular Domain-IGG Fusion Proteins for Three Human Natriuretic Peptide Receptors,”J. BioChem.266:(34):23060-67 (1991).
Braquet, et al.,J. Cardiovascular Pharm.13(Supp. 5):S143-S146 (1989).
Campfield, L.A., et al., “Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Liking Adiposity and Central Neural Networks,”Science, 269:54-549 (1995).
Capon, D., et al., “Designing CD4 Immunoadhesins for AIDS Therapy,”Nature, 337:525-531 (Feb. 9, 1989).
Debs, et al.,J. Immun., 140(10):3482-3488 (1988).
Devos, R., et al., “OB Protein Binds Specifically to the Choroid Plexus of Mice and Rats,”Proc. Natl. Acad. Sci. USA, 93:5668-5673 (May 1996).
Ellison, et al., “The Nucleotide Sequence of a Human Immunoglobulin Cγ1 Gene,”Nucleic Acids Research, 10(13):4071-4079 (1982).
Fisher, C., et al., “Treatment of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein,”N. Engl. J. Med., 334:1697-17022 (1996).
Francis,Focus on Growth Factors, 3:4-10 (1992).
Haak-Frendscho, M. et al., “Inhibitin of Interferon-y by an Interferon-γ Receptor Immunoadhesin,”Immunology, 79:594-599 (1993).
Halaas, et al., “Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene,”Science, 269:543-546 (1995).
Harvey, et al.,Remington's Pharmaceutical Sciences, 18thEd., (Mack Publishing Co., Easton, PA, ed. Gennaro 1990), p. 948-1001.
Harvill, E. et al., “An IgG3-IL2 Fusion Protein Activates Complement, Binds FcγRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R,”Immunotechnology, 1:95-105 (1995).
Ho, S.N. et al., “Site-Directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction,”Gene, 77:51-59 (1989).
Hollenbaugh, et al.,Current Protocols in Immunology, Supp. 4:10.19.1-10.19.11 (1992).
Hubbard, et al.,Annals of Internal Medicine, 111(3):206-212 (1989).
Imagawa, K. et al., “Structure-Function Studies of Human Leptin,”J. Biological Chem., 273(52):35245-49 (1998).
*Kolaczynski, J., et al., “Acute and Chronic Effects of Insulin on Leptin Production in Humans: Studies in vivo and in vitro.”Diabetes45(5):699-701 (1996).
Leshner, et al.,Physiology and Behavior, 9:281-282 (1972).
*Luoh, S-M., et al.,J. Mol. Endo., 18:77-85 (1997).
MacDonald, et al.,Methods in Enzymology, 152:219-227 (1987).
Malik, F., et al., “Polyethylen Glycol (PEG)-modifided Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) with Conserved Biological Activity,”Exp. Hematol., 20:1028-1035 (1992).
Mark, M. et al., “Expression and Characterization of Hepatocyte Growth Factor Receptor-IgG Fusion Proteins,”J. Bio Chem., 267:(36) 26166-71 (1992).
Marshall,Modern Pharmaceutics(Marcel Dekker, Inc., NY, eds. Banker and Rhodes 1979) p. 359-427.
*Mikayama, T., et al. Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor, Nov. 1993,Proc. Natl. Acad. Sci., USA, 90:10056-10060.
Murakami, T., et al., “Cloning of Rat Obese cDNA and Its Expression in Obese Rats,”Biochem. Biophys. Res. Comm., 209(3):944-952 (1995).
Newmark, et al.,J. Appl. Biochem.4:185-189 (1982).
Ngo, et al., The Protein Folding Problem and Tertiary Structure Prediction, pp. 491-495.
Oeswein, et al., “Aerosolization of Proteins,”Proceedings of Symposium on Respiratory Drug Delivery 11, Keystone, CO, Mar. 1990.
Pelleymounter, M.A., et al., “Effects of the Obese Gene Product on Body Weight Regulation in ob/ob Mice,”Science, 269:540-543 (1995).
Prescott, et al.,Microbiology(1990, Wm. C. Brown Publ., Dubuque, IA 52001) p. 599-602.
Remington's Pharmaceutical Sciences, 18thEd. (1990, Mack Publishing Co., Easton, PA 18042) p. 1435-1712 (Table of Contents Provided).
Remington's Pharmaceutical Sciences, 18thEd. (1990, Mack Publishing Co., Easton, PA 18042) Chapter 89 (Table of Contents Provided).
Sambrook, et al.,Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (Table of Contents Provided).
*Skolnick, J., et al., “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era,”Trends in Biotech.18(1):34-39 (Jan. 2000).
Shin, et al.,Intern. Rev. Immunol., 10:177-186 (1993).
Smith, et al.,J. Clin. Invest., 84:1145-1154 (1989).
Stephens, T., et al., “Life Without Neuropeptide Y,”Nature, 377:530-532 (1995).
Stryler, L., et al.,Biochemistry, Third Edition, W H Freeman Company, New York, p. 31-33 (1998).
Sussman, et al.,C.R. Acad. Sci., 254(8):1517-1519 (1962).
Van Zee, K., et al., “Protection Against LethalEscherichia coliBacteremia in Baboons (Papio anubis) by Pretrea
Hecht Randy Ira
Mann Michael B.
Pelleymounter Mary Ann
Toombs Christopher Francis
Amgen Inc.
Chan Christina
Huynh Phuong
Perkins Coie LLP
LandOfFree
OB fusion protein compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with OB fusion protein compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and OB fusion protein compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3575970